卵巢成熟囊性畸胎瘤合并恶性的临床与超声特征
这项国际回顾性观察研究纳入26例组织学证实的卵巢成熟囊性畸胎瘤合并恶性患者,分析其临床与超声特征。结果显示40.0%的肿瘤超声上与良性畸胎瘤无法区分,实性成分(尤其血流丰富)、肿瘤较大、高龄和绝经后状态提示恶性,CA125作用有限。
要点
- 40.0%的畸胎瘤合并恶性在超声上难以与良性畸胎瘤区分。
- 实性成分、血流丰富、肿瘤大、高龄和绝经后提示恶性可能。
- CA125预测恶性作用有限,鳞状细胞癌抗原可能更有用。
核心结论
- 在本系列中,40.0%的成熟囊性畸胎瘤合并恶性在超声上与良性畸胎瘤无法区分。
研究设计与样本
- 国际回顾性观察研究,邀请19个妇科中心,最终9个中心提供26例组织学证实的卵巢成熟囊性畸胎瘤合并恶性病例。
- 由原超声检查者描述肿瘤,并由两名EFSUMB II或III级妇科超声医生回顾图像进行模式识别。
- 采用国际卵巢肿瘤分析(IOTA)术语描述肿瘤。
主要发现
- 患者中位年龄48.5岁(范围14-79岁),17/26(65.4%)为绝经后。
- 最常见恶性组织学为鳞状细胞癌(13/26,50.0%),其次为类癌和黏液性恶性(各5/26,19.2%)、子宫内膜样癌(2/26,7.7%)和神经节胶质瘤(1/26,3.8%)。
- 肿瘤中位最大直径110 mm(范围21-310 mm);黏液性恶性最大(中位210 mm,范围120-310 mm),类癌最小(中位29 mm,范围21-64 mm)。
- 原超声检查者将12/26(46.2%)肿瘤误分类为良性畸胎瘤;回顾图像时10/25(40.0%)表现为典型成熟囊性畸胎瘤。
- 14/26(53.8%)有回声阴影,11/26(42.3%)彩色多普勒血流评分3或4分。
关键数值与推荐
- 实性成分(尤其彩色或能量多普勒显示血流)提示恶性。
- 肿瘤较大、高龄和绝经后状态提高超声检查者对恶性的怀疑。
- 血清CA125在多数成熟囊性畸胎瘤起源的鳞状细胞癌中不升高,作为恶性风险因素作用有限。
- 鳞状细胞癌抗原水平可能更有用。
临床怎么用
- 对绝经后或高龄患者的大型畸胎瘤应仔细评估实性成分和血流。
- 超声发现实性成分或血流丰富时,即使符合畸胎瘤特征也应警惕恶性。
- CA125正常不能排除畸胎瘤恶变,可考虑检测鳞状细胞癌抗原。
局限性
- 回顾性研究,样本量小(26例)。
- 仅9个中心提供病例,可能存在选择偏倚。
- 超声图像回顾仅25例有高质量图像。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To describe the clinical and ultrasound characteristics of ovarian mature cystic teratoma containing malignancy. METHODS: This was an international, retrospective, observational study. We invited 19 (oncological or non-oncological) gynecological centers to provide clinical and ultrasound information on cases of histologically confirmed ovarian mature cystic teratoma containing malignancy. We reported the description of the tumors by the original ultrasound examiner by extracting information from original ultrasound reports and patient records. In addition, two gynecologists, who were European Federation of Societies for Ultrasound in Medicine and Biology Level II or III in gynecological ultrasound, reviewed all available electronic ultrasound images and used pattern recognition with the aim of identifying the typical sonographic features of ovarian mature cystic teratomas containing malignancy. International Ovarian Tumor Analysis terminology was used to describe the tumors throughout. RESULTS: In 10/19 invited centers, no eligible patients were identified. From the databases of nine gynecological centers (three of which were oncological centers), we identified 26 patients with a histologically confirmed malignancy in an ovarian mature cystic teratoma who had undergone preoperative ultrasound examination between September 2012 and August 2024. The median age of the 26 included patients was 48.5 (range, 14-79) years and most (17/26 (65.4%)) were postmenopausal. The most frequent malignant histology was squamous cell carcinoma (13/26 (50.0%)), followed by carcinoid tumor and mucinous malignancy (each 5/26 (19.2%)), endometrioid carcinoma (2/26 (7.7%)) and ganglioglioma (1/26 (3.8%)). Based on the information in the original ultrasound reports, all lesions were unilateral. The median maximum diameter of the ovarian tumors was 110 (range, 21-310) mm. Teratomas containing a mucinous malignancy were the largest (median maximum diameter, 210 (range, 120-310) mm) and teratomas containing a carcinoid tumor were the smallest (median maximum diameter, 29 (range, 21-64) mm). Most tumors containing squamous cell carcinoma, carcinoid tumor, endometrioid cancer or ganglioglioma were described as a unilocular cyst (9/21 (42.9%)) or unilocular-solid cyst (6/21 (28.6%)) by the original ultrasound examiner and most (16/21 (76.2%)) were described as containing cystic content of mixed echogenicity (i.e. the echogenicity typical of a mature cystic teratoma). All five teratomas containing mucinous malignancies were described as a multilocular or multilocular-solid cyst and most (4/5 (80.0%)) were described as containing cystic fluid of low-level or ground-glass echogenicity. Acoustic shadows were described in 14/26 (53.8%) tumors. Eleven of the 26 (42.3%) tumors had moderate or rich vascularization on color Doppler (color score of 3 or 4). The original ultrasound examiner misclassified 12/26 (46.2%) tumors as a benign teratoma. Good-quality ultrasound images were available for 25 tumors. On retrospective review of the ultrasound images using pattern recognition, 10/25 (40.0%) tumors appeared as a typical mature cystic teratoma, 8/25 (32.0%) showed features typical of a mature cystic teratoma but contained a solid component (7/8) or multiple cyst locules (1/8), making them suspicious for malignancy, and 7/25 (28.0%) lacked characteristics typical of a mature cystic teratoma and appeared malignant. CONCLUSIONS: 40.0% of the mature cystic teratomas containing malignancy in our series appeared sonographically indistinguishable from benign teratomas. The presence of solid components within the tumor, especially if vascularized on color or power Doppler, large tumor size, advanced age and postmenopausal status raised the ultrasound examiner's suspicion of malignancy. Serum CA 125 level appears to have a limited role as a risk factor for malignancy, as it is not elevated in most reported cases of squamous cell carcinoma arising in mature cystic teratomas. In contrast, squamous cell carcinoma antigen levels may be more useful. © 2026 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Giudice MT, Moro F, Pozzati F, et al. Imaging in gynecological disease (31): clinical and ultrasound characteristics of ovarian mature cystic teratomas containing malignancies. Ultrasound Obstet Gynecol. 2026. PMID: 42552511. doi:10.1002/uog.70224
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。